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Objective:  The  transient  increase  of  the  cytoplasmic  free calcium  level  plays  a key  role  in the  process  of
lymphocyte  activation.  Kv1.3  and  IKCa1  potassium  channels  are  important  regulators  of the maintenance
of calcium  inﬂux  during  lymphocyte  activation  and  present  a possible  target  for  selective  immunomod-
ulation.
Design:  Case–control  study.
Subjects  and  methods:  We  took  peripheral  blood  samples  from  10 healthy  individuals  and  9  recently
diagnosed  rheumatoid  arthritis  (RA)  patients  receiving  no  anti-rheumatic  treatment.  We  evaluated  cal-
cium inﬂux  kinetics  following  activation  in  CD4,  Th1,  Th2  and  CD8  cells  applying  a novel  ﬂow  cytometry
approach.  We  also  assessed  the sensitivity  of  the  above  subsets  to  speciﬁc  inhibition  of  the  Kv1.3  and
IKCa1  potassium  channels.
Results:  The  peak  of  calcium  inﬂux  in  lymphocytes  isolated  from  RA  patients  is reached  more  rapidly,
indicating  that they  respond  more  quickly  to stimulation  compared  to controls.  In  healthy  individuals,
the  inhibition  of  the  IKCa1  channel  decreased  calcium  inﬂux  in  Th2  and  CD4  cells  to a  lower  extent  than
in Th1  and CD8  cells.  On  the  contrary,  the  inhibition  of  Kv1.3  channels  resulted  in a larger  decrease
of  calcium  entry  in  Th2  and  CD4  than  in Th1  and  CD8  cells.  No  difference  was  detected  between  Th1
and  Th2  or  CD4  and  CD8  cells  in the sensitivity  to  IKCa1  channel  inhibition  among  lymphocytes  of RA
patients.  However,  speciﬁc  inhibition  of  the Kv1.3  channel  acts  differentially  on  calcium  inﬂux  kinetics
in  RA  lymphocyte  subsets.  Th2  and  particularly  CD8  cells  are  inhibited  more  dominantly  than  Th1  and
CD4  cells.
Conclusion:  The  inhibition  of  Kv1.3  channels  does  not  seem  to be  speciﬁc  enough  in peripheral  RA  lym-
mmaphocytes,  since  anti-inﬂa
ntroduction
The short-term activation of peripheral blood and synovial ﬂuid
 lymphocytes, especially that of autoreactive T cells plays a crucial
ole in initiating and maintaining the chronic inﬂammation in the
oints of patients suffering from rheumatoid arthritis (RA). These
ells regulate the inﬂammatory process resulting in the destruc-
ion of the articular cartilage and also play a role in extra-articular
Abbreviations: AUC, area under the curve; [Ca2+]cyt, cytoplasmic free calcium
evel; CRAC, calcium release activated calcium; Max, maximum value; MGTX, mar-
atoxin; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; RA,
heumatoid arthritis; TCM, central memory T cell; TEM, effector memory T cell; tmax,
ime to reach maximum value; TRAM, triarylmethane.
∗ Corresponding author. Tel.: +36 20 4367181; fax: +36 1 3138212.
E-mail address: toldigergely@yahoo.com (G. Toldi).
171-2985/$ – see front matter ©  2012 Elsevier GmbH. All rights reserved.
ttp://dx.doi.org/10.1016/j.imbio.2012.05.013tory  Th2  cells  are  also  affected  to  a noteworthy  extent.
© 2012 Elsevier GmbH. All rights reserved.
damage. The transient increase of the cytoplasmic free calcium
level ([Ca2+]cyt) is a cornerstone in the process of lymphocyte acti-
vation and pathological functioning of lymphocytes in RA. The
engagement of the TCR/CD3 complex upon antigen presentation
leads to calcium release from intracellular stores that is followed
by further calcium entry from the extracellular space through the
store-operated calcium release activated calcium (CRAC) channels.
The inﬂux of calcium is maintained by the function of potassium
channels that conserve the electrochemical potential gradient via
the efﬂux of potassium from the cytoplasm. There are two major
types of potassium channels in T cells: the voltage-gated Kv1.3 and
the calcium-activated IKCa1 channels. Kv1.3 channels are activated
upon the depolarization of the cell and sense alterations of the
membrane potential. In contrast, IKCa1 channels are activated by
the rise of [Ca2+]cyt above 100 nM (Hu et al. 2007; Panyi 2005).
In spite of the increasing number of modern targeted therapeu-
tic strategies (such as anti-TNF alpha or anti-IL-6 agents), there is
3 biology 218 (2013) 311– 316
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Table 1
Clinical characteristics of study participants.
Characteristics Healthy individuals
n = 10
RA patients
n = 9
Age (years) 51 [46–57] 58 [44–61]
Gender (male/female) 4/6 4/5
RA duration (months) – 3 [2–4.5]
RA criteria scoreb – 8 [8–10]
No. of swollen joints – 8 [6.5–13]
No. of tender joints – 14 [11–18]
RF  (U/mL) BLD 96 [62–292]
Anti-MCV (U/mL) BLD 469 [29–963]
CRP  (mg/L) 2.7 [0.0–3.9] 30.6a [16.1–63.0]
We  (mm/h) 10 [7–14] 50a [44–74]
Data are expressed as median [interquartile range] for continuous variables and as
number for categorical variables.
a p < 0.05 vs. healthy individuals.
b According to the latest ACR/EULAR guidelines [7].12 G. Toldi et al. / Immuno
imited data available on their speciﬁc effect on disease-causing
utoreactive lymphocytes. Therefore, novel immunomodulators
ith improved speciﬁcity for autoreactive T cells are needed.
ecent reports raised the notion that the inhibition of lympho-
yte potassium channels, especially that of the Kv1.3 channel would
e an optimal solution for speciﬁc immunosuppression in autoim-
une disorders, including RA (Beeton et al. 2001, 2006; Wulff
t al. 2003). The relationship between the calcium currents through
RAC channels and the efﬂux of potassium makes the proliferation
nd activation of lymphocytes sensitive to pharmacological modu-
ation of Kv1.3 and IKCa1 channels, and provides an opportunity for
argeted intervention. Experimentally, speciﬁc inhibition of these
hannels results in a diminished calcium inﬂux in lymphocytes and
 lower level of lymphocyte activation (Panyi et al. 2006).
Beeton et al. (2006) demonstrated that disease associated
utoreactive T cells isolated from RA patients are principally
CR7-CD45RA- effector memory T cells (TEM cells) with ele-
ated Kv1.3 potassium channel expression, in contrast with naive
nd central memory T cells (TCM cells) that express low levels
f Kv1.3 channels. Hence, Kv1.3 inhibitors preferentially sup-
ress calcium signaling, cytokine production and proliferation
f autoantigen-speciﬁc TEM cells while sparing other classes
f T cells. Furthermore, Beeton and colleagues evaluated the
herapeutic potential of Kv1.3 inhibitors in pristane-induced
hronic arthritis, a rat model of RA. Animals treated with a
peciﬁc blocker of the Kv1.3 channel had signiﬁcantly fewer
ffected joints and showed signiﬁcant improvement in radiological
nd histopathological ﬁndings (Beeton et al. 2006). Addition-
lly, no clinical signs of toxicity were identiﬁed during the
rial.
However, systemic treatment with lymphocyte potassium
hannel inhibitors would affect lymphocytes not only locally
n the synovium, but also those in peripheral blood. Therefore,
n this study we aimed to characterize the effects of lym-
hocyte potassium channel inhibition on short-term peripheral
lood T lymphocyte activation in major lymphocyte subsets of
atients recently diagnosed with RA. We  employed a kinetic
ow cytometry method to describe calcium inﬂux characteris-
ics of the CD4, Th1, Th2 and CD8 subsets and its sensitivity
o the inhibition of Kv1.3 and IKCa1 lymphocyte potassium
hannels.
aterials and methods
atients
We enrolled 10 healthy individuals and 9 recently diagnosed
A patients (early RA patients), who had not received anti-
heumatic treatment, including non-steroidal anti-inﬂammatory
rugs (NSAIDs), disease modifying anti-rheumatic drugs (DMARDs)
nd glucocorticoids until the time of blood sampling. Clinical
arameters of study participants are summarized in Table 1. RA
atients were diagnosed according to the latest ACR/EULAR crite-
ia (Aletaha et al. 2010). Healthy controls had a negative history
f rheumatic symptoms and negative status upon detailed physi-
al and laboratory examination. No co-morbidities were detected
n patients and controls that could have inﬂuenced our investiga-
ion, nor did they take any medication that could have interfered
ith the measurements. Written informed consent was obtained
rom all subjects, and our study was reviewed and approved by an
ndependent ethical committee of the university. Laboratory stud-
es and interpretations were performed on coded samples lacking
ersonal and diagnostic identiﬁers. The study was  adhered to the
enets of the most recent revision of the Declaration of Helsinki.BLD – below the level of detection, CRP – C reactive protein, MCV  – mutated citrulli-
nated vimentin, RA – rheumatoid arthritis, RF – rheumatoid factor, We  – erythrocyte
sedimentation rate.
Fluorescent staining
Our measurements were carried out as described earlier (Toldi
et al. 2011). Brieﬂy, peripheral blood mononuclear cells (PBMCs)
were isolated by a standard density gradient centrifugation from
9 mL  of freshly drawn peripheral venous blood and afterwards
kept in a modiﬁed RPMI medium (calcium concentration: 2 mM)
throughout the following steps of the procedure. PBMCs were
then incubated with the following conjugated anti-human mon-
oclonal antibodies in order to differentiate T lymphocyte subsets
(Fig. 1): anti-CD4 PE-Cy7, anti-CD8 APC-Cy7, anti-CXCR3 APC (for
the determination of Th1 cells) and anti-CCR4 PE (for the deter-
mination of Th2 cells) (all from PharMingen, San Diego, CA, USA),
as well as anti-Kv1.3 channel FITC (Sigma–Aldrich, St. Louis, MO,
USA), according to the manufacturers’ instructions. For monitoring
[Ca2+]cyt, PBMCs were loaded with calcium sensitive Fluo-3 and
Fura-Red dyes according to the manufacturer’s recommendations
(Invitrogen, Carlsbad, CA, USA).
Flow cytometry
PBMCs were equally distributed into three vials. The ﬁrst vial
was used as control. The second vial was treated with margatoxin
(MGTX, 60 nM), a selective blocker of the Kv1.3 channel. The third
vial was  treated with a triarylmethane compound (TRAM, 60 nM),
a speciﬁc inhibitor of the IKCa1 channel. PBMCs were activated by
the addition of 20 g phytohemagglutinin (PHA) and the measure-
ments were initiated directly afterwards on a BD FACSAria ﬂow
cytometer. Cell ﬂuorescence data were measured and recorded for
10 min in a kinetic manner.
Data evaluation
Recordings were evaluated with our speciﬁc software (FacsKin),
based on the calculation of a double-logistic function for each
recording (Kaposi et al. 2008; Toldi et al. 2011). This function is
used to characterize measurements that have an increasing and a
decreasing intensity as time passes. The software also calculated
parameter values describing each function, such as the Area Under
the Curve (AUC), Maximum (Max), time to reach maximum (tmax),
and Slope values. AUC values correspond to the sum of [Ca2+]cyt
increase, which further corresponds to the level of lymphocyte
activation (Panyi 2005). Max  values represent the peak value of
the calcium inﬂux curve upon lymphocyte activation. tmax values
describe how soon the peak value of the calcium inﬂux curve is
reached. The Slope value reﬂects how rapidly the peak of calcium
G. Toldi et al. / Immunobiology 218 (2013) 311– 316 313
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tatistics
Data are expressed as median and interquartile range. Com-
arisons between two sample groups were made with the
ann–Whitney test. For comparisons between paired values in the
ame group Wilcoxon tests were applied. p values less than 0.05
ere considered signiﬁcant. Statistics were calculated using the R
oftware.
esults
linical data
As seen in Table 1, the age and gender distribution of participants
ere similar in both study groups. Inﬂammatory parameters (ery-
hrocyte sedimentation rate and C reactive protein values) were
igher in RA patients than in healthy controls.
he frequency of the investigated lymphocyte subsets
We determined the frequency of CD4, Th1, Th2 and CD8, cells
n samples of both study groups (Table 2). CD4+ CXCR3+ cells
ere regarded as Th1 lymphocytes, while CD4+ CCR4+ cells were
egarded as the Th2 subset. While no signiﬁcant difference was
etected regarding individual cell subsets among the study groups,
he ratio of Th1 and Th2 cells was signiﬁcantly lower in the RA group
n comparison with healthy individuals.
alcium inﬂux kinetics during lymphocyte activationThe calculated parameter values (AUC, Max, tmax and Slope)
ere compared following lymphocyte activation with PHA
etween healthy subjects and RA patients. The parameters are
able 2
revalence of lymphocyte subsets in the overall lymphocyte population gated
ccording to Forward Scatter Characteristics (FSC) and Side Scatter Characteristics
SSC) in 10 healthy individuals and 9 recently diagnosed RA patients.
Subset Healthy RA
CD4+/ly 38.6 [33.0–53.1] 41.8 [34.8–48.1]
CXCR3+/CD4 43.5 [35.5–51.0] 40.2 [29.7–46.7]
CCR4+/CD4 17.7 [11.4–22.8] 24.0 [17.0–30.4]
CD4+ CXCR3+/
CD4+ CCR4+ ratio
3.03 [1.82–3.82] 1.50a [1.10–2.80]
CD8+/ly 15.7 [8.80–23.6] 9.40 [7.64–18.5]
ata are expressed as median [interquartile range]. CD4+ CXCR3+ – Th1 subset, CD4+
CR4+ – Th2 subset, ly – overall lymphocyte population, RA – rheumatoid arthritis.
a p < 0.05 vs. healthy individuals (CD4+ CXCR3+) and Th2 (CD4+ CCR4+) cells. ly – lymphocytes.
shown in Table 3 and Fig. 2. Slope values showed no alteration
between the study groups in the investigated lymphocyte subsets,
and therefore are not included in Table 3. Within the CD4 popula-
tion, AUC and tmax values of calcium inﬂux were decreased in RA
patients compared with healthy controls. When focusing on the
Th1 subset, the decrease was  present in the AUC, Max  and tmax val-
ues, while in Th2 lymphocytes solely the tmax value was lower. We
found no difference in the parameters of calcium inﬂux in the CD8
subset.
The effects of potassium channel inhibitors on lymphocyte calcium
inﬂux
We evaluated the effect of speciﬁc inhibitors of the Kv1.3 and
IKCa1 channels (MGTX and TRAM, respectively) on parameter val-
ues of calcium inﬂux in both study groups. Results are shown in
Table 3 and Fig. 2. Slope values showed no alteration in the inves-
tigated lymphocyte subsets of the study groups upon inhibitor
treatment. MGTX and TRAM treatment decreased AUC values of all
investigated lymphocyte subsets in samples of both study groups.
The Max  value was decreased in all investigated lymphocyte sub-
sets of healthy individuals and RA patients by MGTX. TRAM induced
a decrease in the Max  value of Th1, Th2 and CD8 cells isolated from
healthy individuals, and in all investigated lymphocyte subsets of
RA patients. The tmax value was  only decreased by TRAM in the
CD8 subset of RA patients. The extent of the decrease in parameter
values was  characteristic for the investigated study group and the
inhibited potassium channel in each subset, as detailed in “Discus-
sion”.
Kv1.3 channel expression in the investigated lymphocyte subsets
We evaluated the median ﬂuorescence of the antibody against
Kv1.3 channels in lymphocytes of both study groups. Median
ﬂuorescence was  higher in RA patients compared with healthy
individuals in the CD4+ (54 [39–64] vs. 37 [22–43] arbitrary
units, p < 0.05 (median [interquartile range])) and the CD4+
CXCR3+ (53 [36–69] vs. 14 [4–25] arbitrary units, p < 0.05 (median
[interquartile range])) subsets. No signiﬁcant alterations were
found in the median ﬂuorescence in the CD4+ CCR4+ and CD8+
subsets.
Basal cytoplasmic calcium levels in the investigated lymphocyte
subsets
We evaluated the ratio of the basal median ﬂuorescence
of calcium binding dyes in lymphocytes of both study groups.
Basal median ﬂuorescence was  higher in RA patients compared
with healthy individuals in the CD4+ (11,605 [5617–14,104] vs.
7858 [3922–10,743] arbitrary units, p < 0.05 (median [interquar-
tile range])), the CD4+ CCR4+ (11,064 [7188–14,631] vs. 5920
314 G. Toldi et al. / Immunobiology 218 (2013) 311– 316
Table 3
The effects of the speciﬁc inhibitor of the Kv1.3 channel, margatoxin (MGTX) and the speciﬁc inhibitor of the IKCa1 channel, triarylmethane (TRAM) application on parameter
values  (AUC – Area Under the Curve in units (U), Max  – maximum value in relative parameter value (rpv), tmax – time to reach maximum value in seconds (s)) of calcium
inﬂux  kinetics in peripheral lymphocytes obtained from 10 healthy individuals and 9 recently diagnosed RA patients.
Subset No inhibitor MGTX (60 nM)  TRAM (60 nM)
Healthy RA Healthy RA Healthy RA
CD4+
AUC (U) 790 [738–871] 676a [665–787] 89%b [83–93%] 91%c [88–96%] 93%b [89–97%] 93%c [90–96%]
Max  (rpv) 1.383 [1.228–1.647] 1.297 [1.183–1.390] 94%b [83–99%] 89%c [80–90%] 95% [90–100%] 90%c [88–99%]
tmax (s) 416 [261–563] 174a [140–309] 90% [39–184%] 117% [111–171%] 99% [89–132%] 98% [80–127%]
CD4+
CXCR3+
AUC (U) 897 [805–1006] 761a [719–797] 91%b [84–94%] 93%c [85–93%] 86%b [85–93%] 92%c [88–94%]
Max  (rpv) 1.660 [1.466–1.846] 1.387a [1.279–1.439] 87%b [82–97%] 90%c [84–92%] 89%b [85–94%] 91%c [86–93%]
tmax (s) 396 [227–515] 289a [168–358] 118% [66–162%] 108% [26–196%] 116% [92–221%] 82% [58–117%]
CD4+
CCR4+
AUC (U) 790 [751–857] 735 [697–777] 86%b [84–93%] 89%c [85–94%] 92%b [88–94%] 91%c [88–96%]
Max  (rpv) 1.459 [1.249–1.574] 1.357 [1.277–1.462] 88%b [79–90%] 84%c [79–91%] 88%b [86–98%] 91%c [82–94%]
tmax (s) 365 [214–537] 192a [151–273] 110% [64–174%] 104% [99–132%] 125% [97–164%] 91% [88–113%]
CD8+
AUC (U) 831 [742–950] 821 [734–905] 96%b [87–98%] 85%c [78–89%] 89%b [83–91%] 91%c [85–93%]
Max  (rpv) 1.462 [1.260–1.918] 1.545 [1.282–1.620] 92%b [88–97%] 86%c [78–88%] 85%b [77–89%] 89%c [87–93%]
tmax (s) 326 [253–478] 368 [212–501] 97% [68–133%] 110% [37–126%] 108% [68–163%] 59%c [49–92%]
CD4+, CD4+ CXCR3+, CD4+ CCR4+ and CD8+ cells were gated from the overall lymphocyte population. Data are expressed as median [interquartile range]. CD4+ CXCR3+ –
Th1  subset, CD4+ CCR4+ – Th2 subset, RA – rheumatoid arthritis.
ted fr
or app
or app
[
r
a
D
i
F
ha Lymphocytes isolated from RA patients were compared with lymphocytes isola
b MGTX and TRAM treated samples were compared with samples with no inhibit
c MGTX and TRAM treated samples were compared with samples with no inhibit
3123–9863] arbitrary units, p < 0.05 (median [interquartile
ange])) and the CD8+ (9486 [6072–14,922] vs. 6445 [3477–14,673]
rbitrary units, p < 0.05 (median [interquartile range])) subsets.iscussion
In this study, we investigated T lymphocyte calcium inﬂux kinet-
cs following activation in peripheral blood of recently diagnosed
ig. 2. Alterations of AUC (area under the curve) values upon speciﬁc inhibition of Kv1
ealthy individuals and rheumatoid arthritis (RA) patients. * p < 0.05 vs. control, graph–mom healthy individuals within samples with no inhibitor application, p < 0.05.
lication within lymphocytes isolated from healthy individuals, p < 0.05.
lication within lymphocytes isolated from RA patients, p < 0.05.
RA patients compared to healthy individuals. An advantage of our
investigation is that all patients were enrolled very soon after the
onset of disease (a few months after the presentation of the ﬁrst
symptoms). Therefore, they had not received any anti-rheumatic
treatment until the time of blood sampling. It is important to note
that they were diagnosed according to the latest ACR/EULAR guide-
lines (Aletaha et al. 2010) and all fulﬁlled the criteria of early
deﬁnitive RA.
.3 and IKCa1 lymphocyte potassium channels (MGTX and TRAM, respectively) in
edian, whisker–interquartile range.
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Fig. 3. The effects of Kv1.3 and IKCa1 potassium channel inhibitors on calcium
inﬂux kinetics in CD8 lymphocytes of recently diagnosed RA patients (data of a
representative sample). Kinetic ﬂow cytometry measurements indicate that com-
pared to lymphocytes with no inhibitor treatment, the application of margatoxin
(MGTX), the speciﬁc blocker of the Kv1.3 channel resulted in a greater decrease ofG. Toldi et al. / Immuno
h1/Th2 ratio in RA patients and healthy subjects
Based on the expression of cell surface chemokine receptors,
he Th1/Th2 ratio was lower in RA patients than in healthy sub-
ects. Although the difference of CD4+ CCR4+ (Th2) cell frequency
id not reach the level of statistical signiﬁcance in our study,
e observed a tendency of higher frequency of this subset in
A patients in comparison with healthy individuals in peripheral
lood. The increased expression of CCR4 has been previously noted
y other investigations in RA, ankylosing spondylitis, and systemic
upus erythematosus (Szalay et al. 2012; Yang et al. 2004). Fur-
hermore, Yang et al. (2004) demonstrated that the frequency of
D4+ CCR4+ cells was closely correlated with the elevated serum
evel of IL-10 in these disorders. These ﬁndings indicate that Th2
esponses might be enhanced in the above mentioned diseases.
lthough RA is regarded as a Th1 polarized disease based on the ele-
ated presence of pro-inﬂammatory cytokines (Bucht et al. 1996;
olhain et al. 1996; van der Graaff et al. 1999), Th2 responses might
lso be enhanced in peripheral blood, however, the immunoregu-
atory role of Th2 cells may  be insufﬁcient to control increased Th1
esponses.
alcium inﬂux kinetics in RA patients and healthy subjects
In line with our previous study in another autoimmune disor-
er, multiple sclerosis, we found that lymphocytes isolated from RA
atients respond more quickly to stimulation than those of healthy
ndividuals (Toldi et al. 2011). This is represented by lower tmax
alues, i.e. calcium inﬂux reaches its peak earlier upon activation
ompared to healthy controls (Table 3). This ﬁnding is especially
elevant in the Th2 subset, also indicating that Th2 responses
ight be enhanced in RA to control the ongoing inﬂammation. The
ncreased reactivity of RA lymphocytes has already been noted by
revious investigations. Buntinx et al. demonstrated that RA T cells
how a sustained elevation of [Ca2+]cyt compared with healthy con-
rols when activated in the presence of interferon (IFN) gamma,
long with a signiﬁcantly augmented proliferation in response to
uboptimal doses of PHA. Their results suggest that the IFN gamma-
nduced calcium inﬂux acts as a complementary mechanism in
he activation of T cells from RA patients besides the conventional
CR/CD3-mediated pathway (Buntinx et al. 2002).
asal [Ca2+]cyt levels in RA patients and healthy subjects
The ﬁndings of our study indicate that basal [Ca2+]cyt was ele-
ated in RA compared to healthy individuals. Nagy et al. also
emonstrated earlier that peripheral blood T lymphocytes of RA
atients are characterized by an increase in intracellular nitric oxide
NO) production along with elevated basal [Ca2+]cyt levels (Nagy
t al. 2008). An important outcome of their ﬁnding might be the
ffects of [Ca2+]cyt on gene expression, in particular that of inﬂam-
atory cytokine. Distinct characteristics of calcium inﬂux kinetics
ave been demonstrated to differentially inﬂuence the production
f pro- and anti-inﬂammatory cytokines (Dolmetsch et al. 1998;
erheugen and Vijverberg 1995).
he effects of potassium channel inhibitors on lymphocyte calcium
nﬂux
Our results revealed that the sensitivity of Th1 and Th2 cells
o IKCa1 channel inhibition was different in lymphocytes iso-
ated from healthy individuals. Treatment with TRAM, the speciﬁc
nhibitor of the IKCa1 channel decreased calcium inﬂux in Th2 cells
o a lower extent than in Th1 cells. On the contrary to IKCa1, the
nhibition of Kv1.3 channels resulted in a larger decrease of cal-
ium entry in Th2 than in Th1 cells. This is in line with previouscalcium entry (represented by relative parameter value) than that of triarylmethane
(TRAM), the speciﬁc inhibitor of the IKCa1 channel upon activation of samples with
phytohemagglutinin.
ﬁndings of ours and others (Fanger et al. 2000; Toldi et al. 2012). In
healthy individuals, CD4 cells were more sensitive to the inhibition
of Kv1.3 channels than the CD8 subset, responding with a higher
level of decrease of the AUC value upon the application of MGTX.
However, upon treatment with TRAM, CD8 cells showed a larger
decrease in AUC and Max  values than CD4 cells (Table 3).
In contrast with healthy subjects, no difference was detected
between Th1 and Th2 or CD4 and CD8 cells in the sensitivity
to IKCa1 channel inhibition among lymphocytes of RA patients.
The difference in the decrease of AUC upon MGTX treatment was
also smaller in RA than in healthy controls, however, the decrease
was still more considerable in Th2 cells. Furthermore, in RA lym-
phocytes, MGTX inhibited CD8 cells to a higher extent instead of
CD4 cells. These results indicate that MGTX, a speciﬁc blocker of
the Kv1.3 channel acts differentially on calcium inﬂux kinetics in
major peripheral blood lymphocyte subsets of RA patients: Th2 and
CD8 cells are inhibited more dominantly than Th1 and CD4  cells
(Table 3).
Kv1.3 channel expression in RA patients and healthy subjects
The above mentioned results may  be due to altered function-
ality or changes in the expression of Kv1.3 channels. Therefore,
we measured the expression of these channels on the investigated
lymphocyte subsets using a speciﬁc antibody. However, changes to
the sensitivity of Kv1.3 channel inhibition seem to be unrelated to
its altered expression, and therefore, do not explain our ﬁndings.
Hence, functional alterations of the Kv1.3 channel must also play a
role in differential sensitivity upon inhibition detected between RA
patients and healthy controls. Of note, due to the lack of commer-
cially available antibodies against the other investigated potassium
channel, we  could not perform a similar measurement in case of
IKCa1.
The speciﬁcity of Kv1.3 channel inhibition in RA patients
Based on our results, the immunomodulatory effect of Kv1.3
channel inhibition is predominantly seen in cytotoxic (CD8) T cells
in RA (Fig. 3). However, this effect does not seem to be as spe-
ciﬁc as reported before by Beeton and colleagues in case of TEM
cells (Beeton et al. 2006), since anti-inﬂammatory Th2 cells are also
affected to a noteworthy extent. This subset has an important role in
counterbalancing the ongoing inﬂammatory process, and therefore
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ts inhibition is not useful in the treatment of RA. A reason for lim-
ted speciﬁcity of Kv1.3 inhibition in peripheral lymphocytes might
e the differential distribution of disease-associated autoreactive T
ells in RA patients on local and systemic levels. In the synovial ﬂuid
locally), autoreactive TEM cells, expressing high numbers of Kv1.3
hannels are abundantly present. However, this Kv1.3 pattern was
ot detected in peripheral blood T cells, because autoreactive TEM
ells are infrequent in the circulation. Peripheral blood T cells were
redominantly found to be naive and TCM cells (Beeton et al. 2006).
onclusion
In conclusion, speciﬁc inhibition of the Kv1.3 channel acts dif-
erentially on calcium inﬂux kinetics in major peripheral blood
ymphocyte subsets of RA patients. Th2 and in particular CD8 cells
re inhibited more dominantly than Th1 and CD4 cells. Changes to
he sensitivity of Kv1.3 channel inhibition seem to be unrelated to
ts altered expression in the investigated lymphocyte subsets. The
nhibitory effect does not seem to be as speciﬁc as reported before
n case of autoreactive T cells, since anti-inﬂammatory Th2 cells are
lso affected to a noteworthy extent. A reason for limited speciﬁcity
f Kv1.3 inhibition in peripheral lymphocytes might be the differ-
ntial distribution of disease-associated autoreactive T cells in RA
atients in the synovial ﬂuid and the circulation.
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